Miller CH. The clinical genetics of hemophilia B (factor IX deficiency). Appl Clin Genet. 2021;14:445–54.

Article  CAS  Google Scholar 

Samelson-Jones BJ, George LA. Adeno-associated virus gene therapy for hemophilia. Annu Rev Med. 2023;74:231–47.

Article  CAS  Google Scholar 

Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158.

Article  Google Scholar 

George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215–27.

Article  CAS  Google Scholar 

Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342–7.

Article  CAS  Google Scholar 

Monahan P, Walsh C, Powell J, et al. Update on a phase 1/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B [abstract no. LB010]. J Thromb Haemost. 2015;13(Suppl 2):010.

Google Scholar 

Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21):1994–2004.

Article  Google Scholar 

Crudele JM, Finn JD, Siner JI, et al. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood. 2015;125(10):1553–61.

Article  CAS  Google Scholar 

Pfizer Canada ULC. PrBEQVEZTM (fidanacogene elaparvovec): Canadian prescribing information 2023. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103268. Accessed 8 Jan 2024.

Spark Therapeutics. Spark Therapeutics Launched with $50 Million in Financing to Advance Late- and Mid-Stage Gene Therapy Programs with Clinical Proof of Concept [media release]. https://www.prnewswire.com/news-releases/spark-therapeutics-launched-with-50-million-in-financing-to-advance-late--and-mid-stage-gene-therapy-programs-with-clinical-proof-of-concept-228752221.html. Accessed 22 Oct 2013.

Spark Therapeutics. Amedment to form S-1. 2015. https://www.sec.gov/Archives/edgar/data/1609351/000119312515013888/d776249ds1a.htm. Accessed 28 Jan 2024.

Pfizer. Spark Therapeutics and Pfizer announce that SPK-9001, an investigational hemophilia B Medicine, has been granted access to the PRIority MEdicines (PRIME) program by the European Medicines Agency [media release]. https://sparktx.com/press_releases/spark-therapeutics-and-pfizer-amend-license-agreement-for-investigational-spk-9001-in-hemophilia-b/. Accessed 1 Mar 2017.

Spark Therapeutics. Spark Therapeutics reports 2017 financial results and recent business progress. 2018. https://sparktx.com/press_releases/spark-therapeutics-reports-2017-financial-results-and-recent-business-progress/. Accessed 28 Jan 2024.

Roche. Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy [media release]. https://www.roche.com/media/releases/med-cor-2019-12-17b. Accessed 17 Dec 2019.

George LA, Sullivan SK, Rasko JEJ, et al. Efficacy and safety in 15 hemophilia B patients treated with the AAV gene therapy vector fidanacogene elaparvovec and followed for at least 1 year [abstract no. 3347]. Blood. 2019;134(Suppl 1):3347.

Article  Google Scholar 

Frenzel L, Alzahrani H, Cuker A, et al. Vector clearance following administration of fidanacogene elaparvovec gene therapy in adults with haemophilia B [abstract no. PO132]. Haemophilia. 2024;30(Suppl 1):124–5.

Google Scholar 

Cuker A, Alzahrani H, Astermark J, et al. Efficacy and safety of fidanacogene elaparvovec in adults with moderately severe or svere hemophilia B: results from the phase 3 BENEGENE-2 gene therapy trial [abstract no. OC 52.3]. Res Pract Thromb Haemost. 2023;7(Suppl 2):124–5.

Google Scholar 

Frenzel L, Kavakli K, Klamroth R, et al. Characterizing a cohort of patients with hemophilia B treated with fidanacogene elaparvovec from the phase 3 BENEGENE-2 study who returned to factor IX prophylaxis. Blood. 2023;142(Suppl 1):2257.

Article  Google Scholar 

von Mackensen S, Bagot CN, Lienhart A, et al. Health-related quality of life in adults with haemophilia B after gene therapy with fidanacogene elaparvovec in the BENEGENE-2 trial [abstract no. PO116]. Haemophilia. 2024;30(Suppl 1):92.

Google Scholar 

Rasko JEJ, Chhabra A, Ducore JM, et al. Patterns of joint bleeds in patients with hemophilia B following fidanacogene elaparvovec adeno-associated virus gene therapy. Haemophilia. 2023;29(Suppl 1):113–4.

Google Scholar 

Samelson-Jones BJ, Sullivan SK, Rasko JEJ, et al. Follow-up of more than 5 years in a cohort of patients with hemophilia B treated with fidanacogene elaparvovec adeno-associated virus gene therapy. Blood. 2021;138(Suppl 1):3975.

Article  Google Scholar 

von Mackensen S, Ducore JM, George LA, et al. Health-related quality of life in adults with hemophilia B after receiving gene therapy with fidanacogene elaparvovec. Blood. 2023;142(Suppl 1):3628.

Article  Google Scholar